WCLC 2019 Press Conference - Saturday Sept. 7, 2019

(1:8:53)

WCLC 2019 Press Conference - Monday September 9, 2019

(53:24)

WCLC 2019 Press Conference - September 10, 2019 - IASLC

(49:24)

WCLC 2019 Press Conference - September 08, 2019 - IASLC

(44:53)

WCLC 2019: David Heigener discussing anti-angiogenic vs immune checkpoint inhibitor

(1:1econd)

WCLC 2019: Myung-Ju Ahn discussing 'My personal view on hyperprogression'

(1:3)

Expert highlights from WCLC 2019 | Ross Camidge

(1:52)

IASLC WCLC 2019 Travel Awards

(2:4)

Myung-Ju Ahn presents for a symposium at IASLC 20th WCLC 2019

(2:27)

2019 LVC - Round 1 Part 1 - Lizotte, Barsby, Sexton, Paju

(29:25)

2019 LVC - Round 1 Part 2 - Lizotte, Barsby, Sexton, Paju

(28:42)

Vibram Open 2016 - Championship Skins Match - Front 9 - McBeth, Leiviska, Koling, Wysocki

(20:51)

WCA World Championship 2019 MBLD: 47/50 54:18! (PB + 2nd Place)

(6:34)

2019 WILC Semi Final #1 - Iroquois Nationals vs USA Highlights

(2:18)

Canada's FIRST Adaptive Skate Comp- 9Lives No Limits WCMX

(3:5)

NC State - 2019 Spring Commencement - Student Speaker

(10:33)

WCLC 3rd Anniversary Celebration

(1:21:19)

WCLC Western scratch tickets picked by SNGC

(8:31)

2023 Distinguished Service Award Winner Myung Ju Ahn | IASLC WCLC

(3:42)

WCLC 2019: David Heigener discussing clinical trials in second-line treatment

(2:11)

WCLC 2019: Myung-Ju Ahn discussing hyperprogressive disease

(1:5)

WCLC 2019: Enriqueta Felip discussing chemotherapy plus immunotherapy in non-squamous

(4:15)

WCLC 2019: David Heigener discussing 'My personal approach to second-line treatment in 2019'

(1:55)

ALK positive lung cancer – what hope is there for patients? - WCLC 2019

(1:8)

Join Us for the IASLC 2019 World Conference on Lung Cancer (WCLC 2019)

(49)

WCLC 2019: Experts discussing tumor mutational burden

(2:16)

WCLC 2019: Experts discussing options following immunotherapy

(28)

WCLC 2019: Myung-Ju Ahn discussing hyperprogression: phase III studies

(2:2)

WCLC 2019: Enriqueta Felip discussing chemotherapy doublets in first-line treatment

(44)